rs3731211
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_058195.4(CDKN2A):c.193+7291A>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.74 in 151,900 control chromosomes in the GnomAD database, including 41,619 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.74 ( 41619 hom., cov: 32)
Consequence
CDKN2A
NM_058195.4 intron
NM_058195.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.197
Publications
45 publications found
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
- melanoma, cutaneous malignant, susceptibility to, 2Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- melanoma-pancreatic cancer syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
- familial atypical multiple mole melanoma syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- melanoma and neural system tumor syndromeInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.81).
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.814 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CDKN2A | NM_058195.4 | c.193+7291A>T | intron_variant | Intron 1 of 2 | ENST00000579755.2 | NP_478102.2 | ||
| LOC124902130 | XR_007061436.1 | n.5776A>T | non_coding_transcript_exon_variant | Exon 2 of 2 | ||||
| CDKN2A | NM_001363763.2 | c.-4+7973A>T | intron_variant | Intron 1 of 2 | NP_001350692.1 | |||
| CDKN2A | XM_047422597.1 | c.-4+7699A>T | intron_variant | Intron 1 of 2 | XP_047278553.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.740 AC: 112299AN: 151782Hom.: 41602 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
112299
AN:
151782
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.740 AC: 112371AN: 151900Hom.: 41619 Cov.: 32 AF XY: 0.745 AC XY: 55307AN XY: 74264 show subpopulations
GnomAD4 genome
AF:
AC:
112371
AN:
151900
Hom.:
Cov.:
32
AF XY:
AC XY:
55307
AN XY:
74264
show subpopulations
African (AFR)
AF:
AC:
30351
AN:
41466
American (AMR)
AF:
AC:
11952
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
AC:
2400
AN:
3470
East Asian (EAS)
AF:
AC:
4064
AN:
5168
South Asian (SAS)
AF:
AC:
4026
AN:
4818
European-Finnish (FIN)
AF:
AC:
8121
AN:
10594
Middle Eastern (MID)
AF:
AC:
199
AN:
294
European-Non Finnish (NFE)
AF:
AC:
49187
AN:
67788
Other (OTH)
AF:
AC:
1512
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1538
3076
4614
6152
7690
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
854
1708
2562
3416
4270
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2807
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.